Cancer therapeutic agent mediated by alk

A compound targeting ALK-mediated cancers by inhibiting ALK tyrosine kinase activity effectively addresses the limitations of current cancer treatments by significantly reducing tumor growth and improving survival rates in preclinical models, offering a promising approach for treating ALK-mediated cancers.

WO2024242360A1PCT designated stage expired Publication Date: 2024-11-28ONCOBIX CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/005884
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-29
Filing Date
2024-04-30
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current cancer treatments are inadequate in effectively targeting and inhibiting ALK-mediated cancers, which are caused by the abnormal activation of the Anaplastic Lymphoma Kinase (ALK) gene, leading to excessive cell proliferation and tumorigenesis in various types of cancer, including non-small cell lung cancer and anaplastic large cell lymphoma.

Method used

A cancer treatment agent comprising a specific compound represented by Formula 1, which inhibits the ALK tyrosine kinase activity, competitively binds to ALK, and blocks the ALK signaling pathway, thereby inhibiting tumor cell proliferation and metastasis, is developed. This compound can be administered alone or in combination with other pharmaceutically acceptable carriers and immunomodulatory agents.

Benefits of technology

The compound effectively inhibits the growth of ALK mutant cancer cells, as demonstrated by significant tumor volume reduction and increased mouse survival rates in preclinical studies, showing superior or comparable efficacy to existing ALK inhibitors like Alectinib and Lorlatinib.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024005884_28112024_PF_FP_ABST
    Figure KR2024005884_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides an ALK-mediated cancer therapeutic agent comprising a compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof. The cancer therapeutic agent effectively inhibits the growth of cancer cells mediated by ALK or MAPK.
Need to check novelty before this filing date? Find Prior Art

Description

ALK-mediated cancer therapy

[0001] This application claims the benefit of priority to Korean Patent Application No. 10-2023-0067234, filed May 24, 2023, and Korean Patent Application No. 10-2024-0056760, filed April 29, 2024, the entire contents of which are incorporated herein by reference.

[0002] The present invention relates to a cancer treatment agent mediated by ALK.

[0003] According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, with approximately 9.6 million deaths attributed to various cancers in 2018. Beyond the human toll, cancer inflicts trillions of dollars in direct medical costs and lost productivity worldwide. The impact of cancer on patients and their families is profound. For example, the physical and emotional burden of the disease, as well as the financial burden of treatment, significantly impact the lives of patients and their families. Furthermore, cancer can cause long-term health problems and a decline in quality of life for survivors.

[0004] Cancer can affect anyone, regardless of age, gender, or socioeconomic status, and can develop anywhere in the body. The most common cancers include lung, breast, stomach, liver, colon, and prostate cancers. Cancer can be caused by a variety of factors, primarily mutations or overexpression of kinase enzymes. Currently developed anticancer drugs primarily target the inhibition of oncogenic enzyme activity associated with these specific mutations. Mutations in the epidermal growth factor receptor (EGFR) are a representative example of oncogenic enzymes. Furthermore, ALK, KRAS, and ROS1 are known to be involved in the expression, fusion, and rearrangement of various oncogenes.

[0005] The carcinogenic process of ALK (Anaplastic lymphoma kinase) is known to be mainly related to the ALK-NPM (Nucleophosmin) fusion gene observed in anaplastic large cell lymphoma. When ALK is activated by the gene fusion, the tyrosine kinase contained in ALK behaves abnormally, causing cancer. In other words, abnormally activated ALK induces cell proliferation and prevents cell death by interfering with apoptosis.

[0006] ALK interacts with other tyrosine kinases, both normal and oncogene-activated, and activates various other pathways. In particular, within lung cancer cells, the ALK gene fuses with the EML4 (Echinoderm Microtubule-Associated Protein-Like 4) gene to produce the active tyrosine kinase, EML4-ALK, and it has been shown that the oncogenic ability of EML4-ALK is dependent on its enzymatic activity. In addition, Mosse et al. reported ALK gene amplification in approximately 26% of 491 neuroblastoma specimens (Nature. 2008 Oct 16; 455(7215): 930-935). In addition, the ALK gene has been found to be expressed in numerous non-hematopoietic tumors, including large B-cell lymphoma, systemic myelofibroblastic sarcoma, inflammatory myofibroblastic sarcoma, esophageal squamous cell carcinoma, non-small cell lung cancer, rhabdomyosarcoma, myofibroblastic sarcoma, breast cancer, gastric cancer, and melanoma cell lines. In addition, in the rare disease called inflammatory myelofibroblastic tumor, several types of ALK fusion proteins are frequently found, and these fusion proteins are known to be deeply involved in the development of the tumor.

[0007] [Prior Art Literature]

[0008] [Patent Document]

[0009] Republic of Korea Publication Patent No. 10-2022-0051244

[0010]

[0011] The present inventors sought to develop therapeutic agents that effectively inhibit ALK-mediated cancers. As a result, they discovered specific pyrimidine derivatives that exhibited excellent efficacy in the treatment of various cancers through ALK inhibition.

[0012] Therefore, the present invention aims to provide a cancer treatment agent having excellent effects in treating cancer mediated by ALK.

[0013]

[0014] In order to achieve the above purpose, the present invention

[0015] Provided is a cancer treatment agent mediated by ALK, comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:

[0016] [Chemical Formula 1]

[0017]

[0018] In the above formula,

[0019] X and Y are each independently carbon or nitrogen,

[0020] Z is oxygen or an alkyl group having C1 to C4,

[0021] R1 is a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, CF3, or dimethylamine group,

[0022] R2 is an alkyl group of C1 to C4,

[0023] R3 is hydrogen or a halogen group,

[0024] R4 is hydrogen, a halogen group, CN, CF3, a C1 to C4 alkyl group, or an amino carbonyl group,

[0025] R5 is hydrogen or an alkyl group of C1 to C4,

[0026] R6 is an alkyl group of C1 to C4,

[0027] R7 is hydrogen, an amine group substituted with one or more C1 to C4 alkyl groups, or a piperazinyl group substituted or unsubstituted with one or more C1 to C4 alkyl groups,

[0028] In the above, when Z is oxygen, it forms a double bond with S, and S forms a single bond with N. When Z is a C1 to C4 alkyl group, it forms a single bond with S, and S forms a double bond with N.

[0029] Additionally, R4 and R5 can be linked to form pyrrole, imidazole, and thiophene.

[0030]

[0031] In addition, the present invention

[0032] Provided is a use of the compound represented by the above chemical formula 1 for treating cancer mediated by ALK.

[0033] In addition, the present invention

[0034] A pharmaceutical composition for treating cancer mediated by ALK is provided, comprising a compound represented by the above chemical formula 1 as an active ingredient or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0035] In addition, the present invention

[0036] A method of treating an animal having cancer mediated by ALK, comprising administering to the animal an effective amount of the above cancer treatment agent, is provided.

[0037] In addition, the present invention

[0038] Provided is a use of a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical preparation for treating cancer mediated by ALK.

[0039]

[0040] The cancer therapeutic agent of the present invention provides excellent efficacy in the treatment of cancers mediated by ALK. Specifically, the cancer therapeutic agent of the present invention effectively inhibits the growth of ALK-mutant cancer cells.

[0041]

[0042] Figures 1 and 2 are graphs showing the results of measuring the tumor volume increase inhibition efficacy (in-vivo) of the compound of the present invention in mice (Experimental Example 4).

[0043] Figure 3 is a graph showing the results of increased mouse survival rate according to the tumor volume increase inhibition effect (in-vivo) of the compound of the present invention (Experimental Example 4).

[0044] Figures 4 to 7 are graphs showing the tumor treatment effect of the compound of the present invention in mice (Experimental Example 5).

[0045]

[0046] Hereinafter, the present invention will be described in detail with specific implementation examples. However, these are provided as examples and are not intended to limit the present invention. The present invention is defined solely by the scope of the claims set forth below. Furthermore, even if a configuration is essential for practicing the present invention, a detailed description of such configuration, which can be easily implemented by a person skilled in the art based on known techniques, will be omitted.

[0047] Unless otherwise stated below, the term “compound of the present invention” or “compound of chemical formula 1” or “compound of chemical formula 1-1” is used as a concept including both the compound itself and its salt.

[0048] As used herein, the term "C1 to C4 alkyl group" means a straight-chain or branched hydrocarbon group having a specified number of carbon atoms, or a cyclic hydrocarbon group having the specified number of carbon atoms. The alkyl group may be, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, cycloalkyl, and the like.

[0049] The term “C3 to C6 cycloalkyl group” in this specification may be selected from a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.

[0050] The term "C1 to C4 alkoxy group" as used herein may be straight-chain or branched. Specifically, it may be selected from methoxy, ethoxy, n-propoxy, or isopropoxy.

[0051] As used herein, the term "C1 to C4 mono- or dialkylamine group" refers to an amine group substituted with one or two C1 to C4 alkyl groups, and may be selected from a methylamine group, a dimethylamine group, an ethylamine group, a diethylamine group, a propylamine group, etc. As used herein, the term "alkylsulfonyl" refers to alkyl-S(O2)-. Here, alkyl is defined above. Substituents not defined above may be interpreted within a range apparent to a person skilled in the art.

[0052]

[0053] The present invention relates to a cancer treatment agent mediated by ALK, comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof:

[0054] [Chemical Formula 1]

[0055]

[0056] In the above formula,

[0057] X and Y are each independently carbon or nitrogen,

[0058] Z is oxygen or an alkyl group having C1 to C4,

[0059] R1 is a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, CF3, or dimethylamine group,

[0060] R2 is an alkyl group of C1 to C4,

[0061] R3 is hydrogen or a halogen group,

[0062] R4 is hydrogen, a halogen group, CN, CF3, a C1 to C4 alkyl group, or an amino carbonyl group,

[0063] R5 is hydrogen or an alkyl group of C1 to C4,

[0064] R6 is an alkyl group of C1 to C4,

[0065] R7 is hydrogen, an amine group substituted with one or more C1 to C4 alkyl groups, or a piperazinyl group substituted or unsubstituted with one or more C1 to C4 alkyl groups,

[0066] In the above, when Z is oxygen, it forms a double bond with S, and S forms a single bond with N. When Z is a C1 to C4 alkyl group, it forms a single bond with S, and S forms a double bond with N.

[0067] Additionally, R4 and R5 can be linked to form pyrrole, imidazole, and thiophene.

[0068]

[0069] The compound represented by the above chemical formula 1 may be in a form in which one or more hydrogens contained in the compound are replaced with deuterium. For example, one or more alkyl groups contained in the compound may be in a form in which one or more hydrogens contained therein are replaced with deuterium. In addition, for example, one or more hydrogens contained in one or more substituents among R1, R6, and R7 may be replaced with deuterium.

[0070]

[0071] The compound represented by the above chemical formula 1 may be the following compound:

[0072] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide;

[0073] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-N-methylmethanesulfonamide;

[0074] N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide;

[0075] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N,P,P-trimethylphosphinic amide;

[0076] N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-7H-purin-6-yl)amino)phenyl)-N-methylmethanesulfonamide;

[0077] N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide;

[0078] N-(2-((5-cyano-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide;

[0079] N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide;

[0080] 2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-4-((2-(N-methylmethylsulfonamido)phenyl)amino)pyrimidine-5-carboxylamide;

[0081] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylethanesulfonamide;

[0082] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylpropane-2-sulfonamide;

[0083] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylcyclopropanesulfonamide;

[0084] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-1,1,1-trifluoro-N-methylmethanesulfonamide;

[0085] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methyl(-N',N'-dimethyl)sulfonamide;

[0086] ((2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)imino)dimethyl-λ 6 -Sulphanone;

[0087] N-(2-((5-cyano-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-N-methylmethanesulfonamide;

[0088] N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide; and

[0089] N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0090] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide;

[0091] N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-N-methylmethanesulfonamide;

[0092] N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0093]

[0094] In the present invention, cancers mediated by ALK may be bladder cancer, brain cancer, breast cancer, cervical cancer, endometrial cancer, colon cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, bone marrow cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, colon cancer, neuroblastoma, rhabdomyosarcoma, glioblastoma, mesenchymal tissue cancer, lymph node cancer, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, inflammatory myofibroblastoma, neuroblastoma, etc.

[0095] In particular, the cancer may be lung cancer, and the lung cancer may be small cell lung cancer or non-small cell lung cancer. Additionally, the breast cancer may include inflammatory breast cancer.

[0096] The above cancer may be a secondary cancer that has metastasized to another organ from the various types of cancer mentioned above.

[0097] In the present invention, “cancer mediated by ALK” means cancer caused by abnormal activation of ALK (Anaplastic lymphoma kinase), and also means cancer caused by mutation (mutation) of ALK.

[0098] ALK is a receptor tyrosine protein kinase. ALK gene rearrangements, point mutations, and gene amplification can cause cancer. ALK rearrangements are strong oncogenic driver genes, with EML4-ALK (echinoderm microtubule-associated protein like 4) and NPM-ALK (nucleophosmin) being common types. ALK gene rearrangements cause ALK phosphorylation before dimerization. Therefore, the ALK fusion protein remains active and activates downstream pathways, leading to excessive cell proliferation and tumorigenesis. For example, 3-7% of non-small cell lung cancer patients have ALK gene rearrangements. Common ALK mutations include L1196M, G1269A, S1206Y, G1202R, C1156Y, L1198F, L1152R, I1171T / N / S, V1180L, E1210K, G1128A, R1061Q, K1062M, T1087I, F1174L / S / I / V / C, F1245C / I / L / V, R1275L / Q, D1091N, A1099T, T1151M / R / T, I1170N / T / S, R1060H, K1062M, A1234T, T10871, G1128A, M1166R, I1170N / S / T, I1250T, These include I1183T, R1192P, A1200V, L1204F, R1231Q, A1234T, L1240V, I1250T, D1270G, Y1278S, G1286R, T13431, G1201E, L1152P, S1203N, S1206C / F, C1269A, etc.

[0099] The ALK-mediated cancer therapeutic agent of the present invention targets ALK, competitively binds to ALK with its endogenous ligand, inhibits tyrosine kinase activation, thereby blocking the ALK signaling pathway and suppressing a series of biological effects, such as tumor cell proliferation and metastasis. Meanwhile, the present invention can also be referred to as an ALK signaling pathway blocker or an ALK kinase inhibitor.

[0100] In the present invention, the cancer mediated by ALK may be a cancer mediated by an ALK mutation. The ALK mutation may specifically include one or more of an ALK gene rearrangement, a point mutation, and a gene amplification. The ALK rearranged gene may be EML4-ALK (echinoderm microtubule associated protein like 4). The above ALK mutations are L1196M, G1269A, S1206Y, G1202R, C1156Y, L1198F, L1152R, I1171T / N / S, V1180L, E1210K, G1128A, R1061Q, K1062M, T1087I, F1174L / S / I / V / C, F1245C / I / L / V, R1275L / Q, D1091N, A1099T, T1151M / R / T, I1170N / T / S, R1060H, K1062M, A1234T, T10871, G1128A, M1166R, I1170N / S / T, I1250T, It may be I1183T, R1192P, A1200V, L1204F, R1231Q, A1234T, L1240V, I1250T, D1270G, Y1278S, G1286R, T13431, G1201E, L1152P, S1203N, S1206C / F, C1269A, etc.

[0101]

[0102] In the present invention, the compound represented by the above chemical formula 1 can be used in the form of a salt derived from an inorganic acid or an organic acid, and for example, it can be used in the form of a salt derived from one or more acids selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid, but is not limited thereto, and the salt form can be prepared and used by a method known in the art.

[0103] The compound represented by Chemical Formula 1 of the present invention may also be in the form of a solvate. The term "solvate" refers to a complex or aggregate formed by one or more solute molecules, i.e., a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof; and one or more solvent molecules. The solvate may be a complex or aggregate formed with various solvent molecules, such as, for example, water, methanol, ethanol, isopropanol, or acetic acid.

[0104] The compounds of the present invention may also be in the form of their stereoisomers. The stereoisomers include all stereoisomers, such as enantiomers and diastereomers. The compounds may be in a stereoisomerically pure form or a mixture of one or more stereoisomers, for example, a racemic mixture. The separation of specific stereoisomers can be performed by any of the conventional methods known in the art. Some examples of the compounds of the present invention may exhibit a greater anticancer effect of a specific stereoisomer than that of the racemic mixture. In this case, the dosage can be reduced by using a specific stereoisomer. Therefore, by isolating a specific stereoisomer, for example, an enantiomer or a diastereoisomer, with a greater killing effect on cancer cells, cancer can be effectively treated.

[0105]

[0106] The present invention

[0107] It relates to the use of a compound represented by the above chemical formula 1 for the treatment of cancer mediated by ALK.

[0108] In addition, the present invention

[0109] The present invention relates to a method for treating an animal having cancer mediated by ALK, comprising administering to the animal an effective amount of the above cancer treatment agent. The animal may be a human or an animal other than a human.

[0110] In addition, the present invention

[0111] Provided is a use of a compound represented by the above chemical formula 1 or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical preparation for treating cancer mediated by ALK.

[0112]

[0113] In one embodiment of the present invention, the cancer treatment agent mediated by ALK may further comprise a pharmaceutically acceptable carrier.

[0114] As described above, a therapeutic agent that further includes a pharmaceutically acceptable carrier, etc., may be referred to as a pharmaceutical composition. The pharmaceutical composition is described below.

[0115] The pharmaceutical composition of the present invention comprises a compound represented by the chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and a pharmaceutically acceptable carrier.

[0116] The pharmaceutical composition of the present invention can be formulated according to a conventional method, and can be prepared in various oral administration forms such as tablets, pills, powders, capsules, syrups, emulsions, and microemulsions, or in parenteral administration forms such as intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal injection, and direct injection into tissue.

[0117] When the pharmaceutical composition of the present invention is prepared in the form of an oral dosage form, any ingredient known in the art may be used as a pharmaceutically acceptable carrier without limitation, as long as it does not interfere with the active expression of the active ingredient.

[0118] In the present invention, a "pharmaceutically acceptable carrier" refers to a substance, generally an inert substance, used in combination with an active ingredient to aid in the application of the active ingredient. The carrier may include, for example, one or more selected from fillers, binders, disintergrants, buffers, preservatives, antioxidants, lubricants, flavoring agents, thickeners, coloring agents, emulsifiers, suspending agents, stabilizers, pH regulators, and isotonic agents.

[0119] Examples of carriers used in the present invention include cellulose, calcium silicate, lactose, dextrose, corn starch, sucrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, emulsifiers, suspending agents, diluents, and the like. When the pharmaceutical composition of the present invention is prepared in the form of an injection, water, saline solution, glucose aqueous solution, pseudo-saccharide aqueous solution, alcohol, glycol, oil, fatty acid, fatty acid ester, glyceride, surfactants, suspending agents, emulsifiers, and the like can be used as the carrier.

[0120]

[0121] The dosage of the cancer treatment agent or pharmaceutical composition of the present invention may vary depending on various factors, such as the patient's condition, route of administration, and the attending physician's judgment. Effective dosages can be estimated from dose-response curves obtained from in vitro or animal model tests. The ratio and concentration of the compound of the present invention present in the administered composition may be determined based on its chemical properties, route of administration, therapeutic dosage, and other factors.

[0122] The dosage of the cancer treatment agent or pharmaceutical composition of the present invention is preferably determined by considering the patient's age, sex, condition, absorption rate of the active ingredient in the body, inactivation rate, and concomitantly administered drug. For example, based on the compound of Chemical Formula 1, it can be injected at 0.0001 mg / kg (body weight) to 100 mg / kg (body weight) per dose. The appropriate number of administrations is approximately 1 to 3 times per day.

[0123]

[0124] The pharmaceutical composition of the present invention may additionally include at least one selected from an immunomodulatory agent, a chemotherapeutic agent, and an immunotherapeutic agent.

[0125] Cytokines suitable for use as the above immunomodulators may be selected from, but are not limited to, interleukin (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, etc.), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), or granulocyte-macrophage colony stimulating factor (GM-CSF).

[0126] Examples of the above chemotherapy drugs include Gemcitabine, Cytarabine, Carboplatin, Cisplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Etoposide, 5-fluorouracil, Irinotecan, Methotrexate, Paclitaxel, Topotecan, Trabectedin, Vincristine, or Vinbrastine.

[0127] Also included are gefitinib, erlotinib, afatinib, dacomitinib, osimertinib, lazertinib, crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, entrectinib, vemurafenib, dabrafenib, trametinib, savolitinib, tivantinib, capmatinib, tepotinib, selpercatinib, BLU-667, larotrectinib, HER2 TDM-1, etc.

[0128] The above-mentioned immuno-oncology agent may be an immune checkpoint inhibitor selected from the group consisting of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (Programmed cell death protein 1), LAG-3 (Lymphocyte Activation Gene-3), TIM-3 (T-cell Immunoglobulin and Mucin-domain containing-3), TIGIT (T-cell Immunoreptor with IG and ITIM domain), or VISTA (V-domain Ig Suppressor of T cell Activation), but is not limited thereto.

[0129] Hereinafter, the present invention will be described in more detail through examples. These examples are intended to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples and experimental examples, in accordance with the gist of the present invention.

[0130]

[0131] Example 1: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0132]

[0133] Example 2: Preparation of N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-N-methylmethanesulfonamide

[0134]

[0135] Example 3: Preparation of N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0136]

[0137] Example 4: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N,P,P-trimethylphosphinic amide

[0138]

[0139] Example 5: N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-7H-purin-6-yl)amino)phenyl)-N-methylmethanesulfonamide

[0140]

[0141] Example 6: N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0142]

[0143] Example 7: N-(2-((5-cyano-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0144]

[0145] Example 8: N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0146]

[0147] Example 9: 2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-4-((2-(N-methylmethylsulfonamido)phenyl)amino)pyrimidine-5-carboxylamide

[0148]

[0149] Example 10: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylethanesulfonamide

[0150]

[0151] Example 11: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylpropane-2-sulfonamide

[0152]

[0153] Example 12: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylcyclopropanesulfonamide

[0154]

[0155] Example 13: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-1,1,1-trifluoro-N-methylmethanesulfonamide

[0156]

[0157] Example 14: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methyl(-N',N'-dimethyl)sulfonamide

[0158]

[0159] Example 15: ((2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)imino)dimethyl--λ 6 -Sulphanone

[0160]

[0161] Example 16: N-(2-((5-cyano-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-N-methylmethanesulfonamide

[0162]

[0163] Example 17: N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0164]

[0165] Example 18: N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide

[0166]

[0167] Example 19: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-(methyl-d3)methanesulfonamide

[0168]

[0169]

[0170] Experimental Example 1: Measurement of the growth inhibitory effect of ALK-expressing Ba / F3 cancer cell lines.

[0171] The growth inhibitory effect of the compounds obtained in the above examples on the ALK-expressing Ba / F3 cancer cell line was measured. The method for measuring anticancer efficacy using the Ba / F3 stable cell line is as follows.

[0172] Gene construction: Wild-type and mutant ALK were purchased from Addgene. All constructs were constructed using retroviral vectors, ultimately converting them into viral particles for infection.

[0173] Construction of a Ba / F3 stable cell line: Murine lymphoid cells were grown in an IL-3-dependent manner. Infection of these cell lines with each mutant ALK construct resulted in oncogenic addiction due to mutant ALK expression, allowing the cells to survive without IL-3. Utilizing this principle, we established a stable cell line without puromycin selection. Briefly, each construct was infected into Ba / F3 cells, and after 48 hours, the medium was replaced to remove IL-3 and the cells were cultured. However, puromycin selection was performed for wild-type ALK.

[0174] Ba / F3 stable cell line verification: All stable cell lines were tested by western blotting to confirm the expression of each construct and ALK activity.

[0175] Confirmation of changes in cellular kinase activity (Western blotting): Each stable cell line was treated with drugs in a concentration-dependent manner, and cells were harvested after 5 hours. Cell lysates were prepared using EBC lysis buffer (50 mM Tris-HCl [pH 8.0], 120 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.3 mM phenylmethylsulfonylfluoride, 0.2 mM sodium orthovanadate, 0.5% NP-40, and 5 U / mL aprotinin). EGFR activity was measured using antibodies against EGFR-related signaling molecules.

[0176] Verification of anticancer effect through MTT assay: 2X10 5 Cells were seeded in 96-well plates. After 24 hours, each drug was dose-dependently treated, and cultured for 72 hours. After 4 hours of reaction with 15 μL MTT reagent, 100 μL 10% SDS was added, and cultured for 24 hours. The final OD change was observed at 595 nm. MTT results were analyzed using prism software. 50 The value was measured.

[0177] IC was the concentration at which each compound inhibited cell growth by 50%. 50 The values ​​were calculated and the results are shown in Table 2 below. For ALK, Ceritinib, Lorlatinib, Brigatinib, Alectinib, and Crizotinib were used as control drugs, and for EGFR, Osimertinib was used.

[0178]

[0179] NA: Not Analyzed

[0180]

[0181] Experimental Example 2: Measurement of Kinase Inhibitory Activity

[0182] The kinase inhibitory activity of the compound of Example 1 and the control drug, alectinib, containing an ALK fusion mutation was measured. Specifically, the IC50 value was calculated based on the concentration at which each compound inhibited kinase activity, and the results are shown in Table 2 below as A, B, C, D, and E.

[0183] In the above, A means IC50 0.0 nM to 0.5 nM, B means IC50 greater than 0.5 nM to 1.0 nM, and C means IC50 greater than 1.0 nM to 5.0 nM.

[0184] The specific experiments were conducted as follows:

[0185] (1) Each kinase in Table 2 below was cultured in 20 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg / mL BSA, 0.1 mM Na3VO4, 2 mM DTT, and 1% DMSO.

[0186] (2) Each sample compound was dissolved in DMSO solvent at each concentration (10 points from 10 uM downward) to prepare a sample solution, which was then added to the culture medium to proceed with the reaction.

[0187] (3) After reacting at room temperature for about 20 minutes, ATP (Sigma-Aldrich) and [g-33P]ATP (PerkinElmer) were added until the final concentration reached 10 uM.

[0188] (4) The reaction was allowed to proceed at room temperature for about 2 hours.

[0189] (5) Filtering was performed using P81 ion exchange cellulose chromatography paper, and unreacted ATP was removed using 0.75% phosphoric acid.

[0190] (6) The inhibition ratio was calculated by comparing the kinase activity ratio between the DMSO-treated group and the group in which kinase and inhibitor were not bound.

[0191] (7) IC50 was calculated using Prism (GraphPad).

[0192]

[0193] As shown in the experimental results in Table 2 above, the compound prepared by Example 1 of the present invention was confirmed to have ALK kinase inhibitory activity similar to or superior to that of alectinib.

[0194]

[0195] Experimental Example 3: Cancer Cell Viability Analysis

[0196] 3.1. Cell culture

[0197] The cancer cell lines shown in Table 3 below were cultured under the indicated culture conditions at 37°C and 5% CO2 in air. Tumor cells were subcultured regularly. Cells growing in the exponential growth phase were harvested and counted.

[0198] Cell lineCancer typeGrowth PropertiesMedium & SerumTC71SarcomaAdherentIMDM + 10% FBSKARPAS-299LeukemiaSuspensionRPMI 1640 + 20% FBS + 2mM GlutamineSU-DHL-1LymphomaSuspensionRPMI 1640 + 10% FBSTOLEDOLymphomaSuspensionRPMI 1640 + 10%FBSSK-N-SHNeuroblastomaAdherentEMEM + 10% FBSMG63OsteosarcomaAdherentEMEM + 10% heat-inactivated FBSMEWOMelanomaAdherentEMEM + 10%FBSKLEEndometrialAdherentDMEM / F12 + 10% FBSHCT116ColorectalAdherentMcCoy's 5a + 10% FBS

[0199] 3.2. Cell plating (1) Cells were counted using a hemocytometer using trypan blue staining.

[0200] (2) The cell concentration was adjusted to an appropriate density as follows.

[0201] TC71 (3000), KARPAS-299 (5000), SU-DHL-1 (5000), TOLEDO (5000), SK-N-SH (4000), MG63 (3000), MEWO (3000), KLE (5000), HCT116 (2000)

[0202] (3) Cells of interest were seeded at an appropriate density (90 uL per 96-well plate). 90 uL of cell culture medium was added to empty wells.

[0203] (4) The plate was incubated overnight in an incubator at 37°C, 5% CO2, 95% air, and 100% relative humidity.

[0204] 3.3. Preparation of sample compound stock plates

[0205] Preparation of sample compound stock plates (400X stock plates): Example 1 Compounds, Alectinib and Lorlatinib, were sequentially diluted in DMSO from the highest to the lowest concentration according to the plate map (Table 4 below) and prepared freshly when used.

[0206] 123456789Alectinib40001333.3444.44148.1549.3816.465.491.830.61Lorlatinib40001333.3444.44148.1549.3816.465.491.830.61Example 140001333.3444.44148.1549.3816.465.491.830.61

[0207] (Unit: uM)

[0208] 4.4. Preparation of sample compound plate (10X) and sample compound treatment

[0209] (1) Prepare 10X concentrated sample compound plate: Add 156 uL of assay medium to each well of a V-bottom plate, then transfer 4 uL of the 400X stock compound solution for each concentration from the stock plate. Add 4 uL of DMSO to the blank and control wells and pipette up and down to mix well.

[0210] (2) Sample compound treatment: 10 uL of sample compound-medium was added to each well of the 10X concentrated compound plate into the 96-well assay plate containing cells. 10 uL of DMSO-medium was added to the blank and control wells. The final DMSO concentration was 0.25%.

[0211] (3) The analysis plate was returned to the incubator and cultured for 3 days.

[0212] 3.5. CellTiter-Glo luminescent cell viability assay

[0213] The procedure was performed according to the Promega CellTiter-Glo luminescent cell viability assay kit (Promega-G7573).

[0214] (1) Before use, thaw the CellTiter-Glo buffer and adjust the temperature to room temperature.

[0215] (2) Before use, the lyophilized CellTiter-Glo substrate was warmed to room temperature.

[0216] (3) The entire liquid volume of CellTiter-Glo buffer was transferred to the amber bottle containing the CellTiter-Glo substrate to reconstitute the lyophilized enzyme / substrate mixture, forming the CellTiter-Glo reagent.

[0217] (4) Gently stir and mix to obtain a uniform solution.

[0218] (5) The temperature of the plate and its contents was adjusted at room temperature for about 30 minutes.

[0219] (6) Add 50 uL of CellTiter-Glo reagent to each well (equivalent to half the volume of culture medium in each well) and cover the plate with aluminum foil to protect from light.

[0220] (7) The mixture was mixed for 2 minutes in an orbital shaker to induce cell lysis.

[0221] (8) The plate was incubated at room temperature for 10 minutes to allow the luminescence signal to stabilize.

[0222] (9) Luminescence was recorded on a 2104 EnVision plate reader.

[0223] 3.6. Data Analysis

[0224] The inhibition ratio (IR) of the tested compounds was determined by the following formula:

[0225] IR (%) = (1- (RLU compound - RLU blank) / (RLU control - RLU blank)) × 100%

[0226] The inhibition ratios of the compound at various doses were calculated. The data were interpreted using Graph Pad Prism (8.0.1). The equation “log(inhibitor) vs. response -- variable slope” was used to fit the dose-response curve. Top and Bottom represent the intervals where the measured values ​​were stable in the Y-axis units. The relative IC50 was the concentration at the midpoint of the curve between Top and Bottom. The absolute IC50 is the drug concentration that inhibits cell viability by half.

[0227]

[0228] NA: Not Analyzed

[0229] As shown in the experimental results in Table 5 above, the inhibitory activity of each compound of Example 1 of the present invention against cancer cells was confirmed to be superior to that of lorlatinib and alectinib.

[0230]

[0231] Experimental Example 4: Measurement of tumor volume increase inhibition efficacy (in vivo)

[0232] 4.1. Cell culture

[0233] Ba / F3_EML4-ALK_G1202R cells were maintained in vitro in suspension culture in RPMI 1640 + 10% FBS + 1% AA at 37°C in an atmosphere containing 25% CO2. These tumor cells were subcultured twice a week by trypsin-EDTA treatment. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.

[0234] 4.2. Tumor inoculation and animal classification

[0235] Each mouse was subcutaneously inoculated into the right flank with Ba / F3_EML4-ALK_G1202R tumor cells (1 × 106+ Matrigel) mixed in 0.2 mL of PBS for tumor development. From day 11 after tumor inoculation, the average tumor size was approximately 100 mm3 Treatment was initiated when the tumor volume reached . Mice were assigned to groups using Excel-based randomization software that performed stratified randomization based on tumor volume. Each group consisted of six tumor-bearing mice.

[0236] Each sample was administered to mice as follows.

[0237] Sample Dosage Concentration Dosage MethodVehicle-PO, QD X 23 days, n=6Alectinib20 mg / kgPO, QD X 23 days, n=6Loriatinib10 mg / kgPO, QD X 28 days, n=6Example 112.5 mg / kgPO, QD X 28 days, n=6Example 125 mg / kgPO, QD X 28 days, n=6Example 150 mg / kgPO, QD X 28 days, n=6

[0238] Note) PO: Oral administration, QD: Once daily administration4.3. ObservationAll procedures related to animal handling, management, and treatment in this study were performed in accordance with the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of WuXi App Tec, which follows the guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). During routine monitoring, animals were checked daily for tumor growth and the effects of treatment on normal behaviors, such as mobility, food and water consumption (visual observation only), body weight gain / loss (weighed three times a week), eye / fur tangles, and other abnormal effects specified in the protocol. Mortality and observed clinical signs were recorded based on the number of animals in each subgroup.

[0239] 4.4. Tumor Measurement and Endpoint

[0240] The primary endpoint was to determine whether the treatment could delay tumor growth or cure the mice. Tumor size was measured in two dimensions three times a week using calipers, and volume was expressed in mm³ using the formula V = 0.5 ax b², where a and b are the long and short diameters of the tumor, respectively. Tumor size was then used to calculate T / C and TGI values.

[0241] T / C(%)=TRTV / CRTV x 100%

[0242] The above TRTV is the mean relative tumor volume of the treatment group, and CRTV is the mean relative tumor volume of the control group. RTV is calculated using the formula RTV = Vn / V0, where V0 is the tumor volume on the first day of treatment and Vn is the tumor volume on a specific day. For calculating T / C(%), TRTV and CRTV on the same day must be used. TGI was calculated for each group using the following formula.

[0243] TGI(%) = [1-(Ti-T0) / (Vi-V0)] ×100

[0244] The above Ti is the mean tumor volume of the treatment group on a given date, T0 is the mean tumor volume of the treatment group on the start date of treatment, Vi is the mean tumor volume of the vehicle control group on the same date as Ti, and V0 is the mean tumor volume of the Vehicle group on the start date of treatment.

[0245] 4.5. Statistical Analysis

[0246] Summary statistics (including the mean and standard error of the mean (SEM)) for tumor volume at each time point for each group are provided. Statistical analysis of differences in tumor volume between groups was performed based on data obtained at the optimal treatment time point (day 17 post-treatment). T-tests were performed to compare tumor volumes between groups. All data were analyzed using Prism 8.0. A p < 0.05 value was considered statistically significant.

[0247]

[0248] The results of the above experiment are shown in Figures 1 to 3. Figure 1 is a graph showing the results of measuring the size of cancer cells (actual size), and Figure 2 is a graph showing the increased size of cancer cells calculated as a percentage compared to the initial size of cancer cells.

[0249] From FIGS. 1 to 3, it was confirmed that the group administered the compound of Example 1 of the present invention showed a significant suppression of tumor volume increase compared to the group administered the Alectinib or Loriatinib.

[0250]

[0251] Experimental Example 5: Measurement of Tumor Treatment Efficacy (In-vivo)

[0252] 5.1. Cell culture

[0253] NCI-H2228-luc cells were maintained in vitro in RPMI 1640 + 10% FBS + 1% AA medium at 37°C in an atmosphere of 5% CO2. These tumor cells were subcultured twice weekly by trypsin-EDTA treatment. Cells growing in the exponential growth phase were harvested and counted for tumor inoculation.

[0254] 5.2. Intracranial tumor inoculation

[0255] BALB / c female nude mice were anesthetized with an intraperitoneal injection of 1.25% avertin at a dose of 20 μL / g. For pain relief, the mice received a subcutaneous injection of meloxicam at a dose of 1 mg / kg (subcutaneously once daily) within 3 days after surgery. The mice were observed until they recovered from anesthesia.

[0256] Anesthetized mice were appropriately positioned. The scalp skin of the mice was sterilized with 70% alcohol and covered aseptically. A 2-3 mm incision was made anterior to the interaural line and immediately to the right of the midline. Each mouse was intracranially inoculated with NCI-H2228-luc cells (1 x 10^5 + 20% Matrigel in 3 μL PBS) into the right frontal lobe, 2 mm lateral and 0.5 mm anterior to the bregma, to a depth of 3.5 mm. The incision site was closed with No. 6 sutures and sterilized again with iodine solution. The mice were kept warm until they recovered from anesthesia.

[0257] 5.3. Mouse Grouping

[0258] Twenty-four mice were selected for efficacy studies when the mean bioluminescence measurement reached 2.50E+05 photons / s on day 5 after tumor implantation. Mice were assigned to groups by stratified randomization using Excel-based randomization software based on bioluminescence intensity.

[0259] Treatment of each sample was performed as follows.

[0260] Test group Sample administration method Group 1 Vehicle PO, QD X 28D, n=6 Group 2 Alectinib 20 mg / kg, PO, QD X 28D, n=6 Group 3 Example 125 mg / kg, PO, QD X 28D, n=6 Group 4 Example 150 mg / kg, PO, QD X 28D, n=6

[0261] PO: Oral administration, QD: Once daily administration 5.4. Bioluminescence measurement and endpoint

[0262] The primary endpoint was to determine whether tumor growth was delayed, tumor metastasis was prevented, or the mice could be cured. Surgically inoculated mice were weighed and intraperitoneally administered 150 mg / kg of luciferin. Ten minutes after luciferin injection, the animals were pre-anesthetized with a mixture of oxygen and isoflurane. Under complete anesthesia, the mice were transferred to an imaging chamber equipped with an IVIS (Lumina III) imaging system for bioluminescence measurements. Bioluminescence of the entire animal, primary tumor, and metastatic tumors was measured and recorded on days 0, 7, 14, 18, 21, and 28. Tumor growth curves were plotted as bioluminescence intensity (photons per second). Tumor bioluminescence was used to calculate T / C values, where T and C are the mean bioluminescence of the treatment and control groups on the corresponding days, respectively. The TGI was calculated for each group using the following formula:

[0263] TGI(%) = [1-(Ti-T0) / (Vi-V0)] Х100

[0264] In the above, Ti is the mean bioluminescence of the treatment group on a specific date, T0 is the mean bioluminescence of the treatment group on the first day of treatment, Vi is the mean bioluminescence of the control group on the same day as Ti, and V0 is the mean bioluminescence of the control group on the first day of treatment.

[0265] 5.5. Observation

[0266] All procedures involving animal care, maintenance, and research were performed in accordance with the approved guidelines of the Institutional Animal Care and Use Committee (IACUC) of WuXi AppTec and followed the guidelines of the Association for Accreditation of Laboratory Animal Care (AAALAC). During routine monitoring, animals were checked daily for tumor growth and the effects of treatment on normal behavior (motility, food and water intake (visual check only), weight gain / loss (weighed three times a week), eye / fur tangles, and other adverse effects specified in the protocol). Mortality and observed clinical signs were recorded based on the number of animals in each subgroup.

[0267] 5.6. Statistical Analysis

[0268] Summary statistics (including means and standard errors of the means (SEM)) for tumor bioluminescence at each time point for each group are provided. Statistical analysis of tumor bioluminescence differences between groups was performed based on data obtained at the optimal treatment time point, day 18 post-treatment. A one-way analysis of variance (ANOVA) was performed on the tumor bioluminescence data, and a significant F statistic (the ratio of treatment variability to error variability) was obtained (p < 0.05). Comparisons between groups were performed using the Games-Howell test. All data were analyzed using Prism GraphPad 9.0, and a p < 0.05 was considered statistically significant.

[0269]

[0270] The above experimental results are shown in Figures 4 to 7. From Figures 4 to 7, it was confirmed that the compound administration group of Example 1 of the present invention and the Alectinib administration group showed significantly superior tumor treatment effects compared to the control group. In addition, it was confirmed that the compound administration group of the present invention showed an equivalent degree of effect in tumor treatment as the Alectinib administration group.

Claims

1. A cancer treatment agent mediated by ALK, comprising a compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof: [Chemical Formula 1] In the above formula, X and Y are each independently carbon or nitrogen, Z is oxygen or an alkyl group having C1 to C4, R1 is a C1 to C4 alkyl group, a C3 to C6 cycloalkyl group, CF3, or dimethylamine group, R2 is an alkyl group of C1 to C4, R3 is hydrogen or a halogen group, R4 is hydrogen, a halogen group, CN, CF3, a C1 to C4 alkyl group, or an amino carbonyl group, R5 is hydrogen or an alkyl group of C1 to C4, R6 is an alkyl group of C1 to C4, R7 is hydrogen, an amine group substituted with one or more C1 to C4 alkyl groups, or a piperazinyl group substituted or unsubstituted with one or more C1 to C4 alkyl groups, In the above, when Z is oxygen, it forms a double bond with S, and S forms a single bond with N. When Z is a C1 to C4 alkyl group, it forms a single bond with S, and S forms a double bond with N. Additionally, R4 and R5 can be linked to form pyrrole, imidazole, and thiophene.

2. In paragraph 1, The compound represented by the above chemical formula 1 is a cancer treatment agent characterized by the following compounds: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide; N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-N-methylmethanesulfonamide; N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide; N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N,P,P-trimethylphosphinic amide; N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-7H-purin-6-yl)amino)phenyl)-N-methylmethanesulfonamide; N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide; N-(2-((5-cyano-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide; N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide; 2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-4-((2-(N-methylmethylsulfonamido)phenyl)amino)pyrimidine-5-carboxylamide; N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylethanesulfonamide; N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylpropane-2-sulfonamide; N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylcyclopropanesulfonamide; N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-1,1,1-trifluoro-N-methylmethanesulfonamide; N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methyl(-N',N'-dimethyl)sulfonamide; ((2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)imino)dimethyl-λ 6 -Sulphanone; N-(2-((5-cyano-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-N-methylmethanesulfonamide; N-(2-((5-chloro-2-((2-methoxy-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide; and N-(2-((2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide 3. In paragraph 1, X is nitrogen, Y is carbon, Z is oxygen, R1 is a C1 to C4 alkyl group, R2 is hydrogen or an alkyl group of C1 to C4, R3 is hydrogen or a halogen group, R4 is a halogen group, R5 is hydrogen, R6 is an alkyl group of C1 to C4, A cancer treatment agent characterized in that R7 is an amine group substituted with one or more C1 to C4 alkyl groups or a piperazinyl group substituted or unsubstituted with one or more C1 to C4 alkyl groups.

4. In paragraph 3, A cancer treatment agent characterized in that the compound represented by the above chemical formula 1 is the following compound: N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide; N-(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-4-fluorophenyl)-N-methylmethanesulfonamide; and N-(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)-N-methylmethanesulfonamide 5. In paragraph 1, A cancer treatment agent characterized in that the salt is a salt derived by at least one acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid.

6. In paragraph 1, A cancer treatment agent characterized in that the cancer mediated by the above ALK is at least one selected from the group consisting of bladder cancer, brain cancer, breast cancer, cervical cancer, endometrial cancer, colon cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, bone marrow cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, thyroid cancer, colon cancer, neuroblastoma, rhabdomyosarcoma, glioblastoma, mesenchymal tissue cancer, and lymph node cancer.

7. In paragraph 1, A cancer treatment agent characterized in that the cancer mediated by the above ALK is non-small cell lung cancer.

8. In paragraph 1, A cancer treatment agent further comprising a pharmaceutically acceptable carrier.

9. A method for treating an animal having cancer mediated by ALK, comprising administering to the animal an effective amount of the cancer treatment agent of paragraph 1.

10. Use of a compound represented by chemical formula 1 of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical preparation for cancer treatment mediated by ALK.

Citation Information

Patent Citations

  • N2,N4-diphenylpyrimidine-2,4-diamine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient

    KR1020180135781A

  • Laser cleaning device

    KR102107377B1

  • Identification recognition device with packaging medicine sorting and transport function

    KR102635075B1

  • KR20190067699A

  • KR20230054567A